ESTIMATED
02/17/2023
02/17/2023
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 0 | $2.14 | $2.14 | $2.14 |
Q2 2024 | 0 | $1.82 | $1.82 | $1.82 |
Q3 2024 | 0 | $2.09 | $2.09 | $2.09 |
InMed Pharmaceuticals Inc. last posted its earnings results on Friday, February 17th, 2023. The company reported $-0.91 earnings per share for the quarter, topping analysts' consensus estimates of $-4.5 by $3.59. The company had revenue of 1.17 M for the quarter and had revenue of 4.14 M for the year. InMed Pharmaceuticals Inc. has generated $-3 earnings per share over the last year ($-3.25 diluted earnings per share) and currently has a price-to-earnings ratio of -0.42. InMed Pharmaceuticals Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, September 27th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/13/2024 | Q3 2024 | -$0.18 | $2.02 M | $1.17 M | 02/13/2024 | Q2 2024 | -$0.19 | $1.49 M | $1.24 M | 11/13/2023 | Q1 2024 | -$0.76 | $1.69 M | 09/29/2023 | Q4 2023 | -$0.10 | $2.31 M | 05/15/2023 | Q3 2023 | -$0.60 | $889,965 | $1.03 M | 02/17/2023 | Q2 2023 | -$4.50 | -$0.91 | 3.59 | $671,821 | $469,783 | 11/14/2022 | Q1 2023 | -$4.06 | $320,788 | 09/23/2022 | Q4 2022 | -$302.39 | $514,758 | 05/13/2022 | Q3 2022 | -$5.75 | -$133.55 | -127.8 | $309,585 | 02/14/2022 | Q2 2022 | -$6.00 | -$9.78 | -3.78 | $125,000 | $265,092 | 11/10/2021 | Q1 2022 | -$8.75 | -$7.81 | 0.94 | $300,000 | $0 | 09/24/2021 | Q4 2021 | -$12.55 | $0 | 05/13/2021 | Q3 2021 | -$6.00 | -$12.91 | -6.91 | $0 | 02/11/2021 | Q2 2021 | -$6.00 | -$11.72 | -5.72 | $0 | 12/16/2020 | Q1 2021 | -$10.20 | $0 | 06/30/2020 | Q4 2020 | -$10.51 | $0 | 03/31/2020 | Q3 2020 | -$13.64 | $0 | 12/31/2019 | Q2 2020 | -$15.50 | $0 | 09/30/2019 | Q1 2020 | -$16.22 | $0 | 06/30/2019 | Q4 2019 | -$20.45 | $0 |
---|
A. InMed Pharmaceuticals Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, September 27th, 2024 based off last year's report dates.
A. In the previous quarter, InMed Pharmaceuticals Inc. (NASDAQ:INM) reported $-0.91 earnings per share (EPS) to beat the analysts' consensus estimate of $-4.5 by $3.59.
A. The conference call for InMed Pharmaceuticals Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for InMed Pharmaceuticals Inc.'s latest earnings report can be read online.
A. InMed Pharmaceuticals Inc. (NASDAQ:INM) has a recorded annual revenue of $4.14 M.
A. InMed Pharmaceuticals Inc. (NASDAQ:INM) has a recorded net income of $4.14 M. InMed Pharmaceuticals Inc. has generated $-3.25 earnings per share over the last four quarters.
A. InMed Pharmaceuticals Inc. (NASDAQ:INM) has a price-to-earnings ratio of -0.42 and price/earnings-to-growth ratio is -0.02.